Nkarta Investor Relations Material
Latest events
FDA Announcement
Nkarta
Q1 2025
14 May, 2025
Q4 2024
26 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Nkarta Inc
Access all reports
Nkarta Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
NKTX
Country
🇺🇸 United States